Sarepta Therapeutics Inc- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Sarepta Therapeutics Inc 公司

Sarepta Therapeutics, Inc. 是一家商业阶段的生物制药公司。该公司致力于通过发现和开发针对核糖核酸 (RNA) 的疗法、基因疗法和其他用于治疗罕见疾病的基因治疗方式来帮助患者。该公司已开发了多种用于治疗杜氏肌营养不良症 (Duchenne) 的获批产品，并正在开发用于治疗一系列疾病和病症的潜在治疗候选药物，包括杜氏肌营养不良症、肢带型肌营养不良症 (LGMD) 和其他神经肌肉和中枢神经系统 (CNS) 相关疾病。该公司已开发并商业化了四种获批的杜氏肌营养不良症治疗产品：EXONDYS 51（eteplirsen）注射液（EXONDYS 51）、VYONDYS 53（golodirsen）注射液（VYONDYS 53）、AMONDYS 45（casimersen）注射液（AMONDYS 45）和ELEVIDYS。其产品线包括约40个处于不同发现、临床前和临床开发阶段的项目。

Sarepta Therapeutics Inc简介



公司代码SRPT

公司名称Sarepta Therapeutics Inc

上市日期Jun 04, 1997

CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.

员工数量1372

证券类型Ordinary Share

年结日Jun 04

公司地址215 First Street

城市CAMBRIDGE

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编02142

电话16172744000

网址https://www.sarepta.com/

公司代码SRPT

上市日期Jun 04, 1997

CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.

Sarepta Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Richard J. (Rick) Barry

Independent Director

3.21M

+1.02%

Mr. Douglas S. (Doug) Ingram, Esq., J.D.

Chief Executive Officer

390.31K

--

Dr. Louise Rodino-Klapac, Ph.D.

President - Research and Development and Technical Operations

201.48K

+249.76%

Mr. Ian Michael Estepan

President, Chief Operating Officer

189.46K

+315.61%

Mr. Ryan Wong

Chief Financial Officer, Executive Vice President

136.20K

+686.03%

Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.

Independent Director

22.84K

-2.30%

Mr. Dallan Murray

Executive Vice President, Chief Customer Officer

21.18K

-44.29%

Ms. Cristin L. Rothfuss

Executive Vice President, General Counsel, Corporate Secretary

--

Ms. Deirdre Connelly

Independent Director

--

Dr. Claude Nicaise, M.D.

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Richard J. (Rick) Barry

Independent Director

3.21M

+1.02%

Mr. Douglas S. (Doug) Ingram, Esq., J.D.

Chief Executive Officer

390.31K

--

Dr. Louise Rodino-Klapac, Ph.D.

President - Research and Development and Technical Operations

201.48K

+249.76%

Mr. Ian Michael Estepan

President, Chief Operating Officer

189.46K

+315.61%

Mr. Ryan Wong

Chief Financial Officer, Executive Vice President

136.20K

+686.03%

Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.

Independent Director

22.84K

-2.30%

收入明细

单位: USD更新时间: 10月6日周一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

业务USD

名称

营收

占比

ELEVIDYS

281.85M

54.93%

PMO Products

231.27M

45.07%

collaboration and other

97.97M

19.09%

地区USD

名称

营收

占比

United States

484.77M

94.48%

Rest of World

28.35M

5.52%

业务

地区

业务USD

名称

营收

占比

ELEVIDYS

281.85M

54.93%

PMO Products

231.27M

45.07%

collaboration and other

97.97M

19.09%

股东统计

更新时间: 11月1日周六

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

10.17%

BlackRock Institutional Trust Company, N.A.

9.40%

D. E. Shaw & Co., L.P.

4.83%

State Street Investment Management (US)

4.49%

Two Sigma Investments, LP

3.96%

其他

67.15%

持股股东

占比

The Vanguard Group, Inc.

10.17%

BlackRock Institutional Trust Company, N.A.

9.40%

D. E. Shaw & Co., L.P.

4.83%

State Street Investment Management (US)

4.49%

Two Sigma Investments, LP

3.96%

其他

67.15%

股东类型

持股股东

占比

Investment Advisor

31.26%

Investment Advisor/Hedge Fund

20.40%

Hedge Fund

20.05%

Research Firm

5.54%

Individual Investor

4.67%

Bank and Trust

1.24%

Pension Fund

1.13%

Sovereign Wealth Fund

0.90%

Insurance Company

0.03%

其他

14.78%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

1017

84.37M

80.60%

-20.51M

2025Q2

1032

95.91M

98.15%

-10.95M

2025Q1

1077

102.36M

104.40%

-6.43M

2024Q4

1057

102.62M

105.91%

-1.51M

2024Q3

1027

96.14M

100.83%

-6.90M

2024Q2

997

94.21M

99.66%

-1.44M

2024Q1

932

88.31M

94.10%

-6.68M

2023Q4

926

87.42M

93.47%

-6.42M

2023Q3

916

88.86M

95.27%

-4.43M

2023Q2

931

87.46M

93.91%

-4.38M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

10.64M

10.17%

+1.51M

+16.51%

Aug 29, 2025

BlackRock Institutional Trust Company, N.A.

9.84M

9.4%

+937.08K

+10.53%

Jun 30, 2025

D. E. Shaw & Co., L.P.

5.06M

4.83%

+581.27K

+12.98%

Jul 18, 2025

State Street Investment Management (US)

4.70M

4.49%

+626.55K

+15.40%

Jun 30, 2025

Two Sigma Investments, LP

4.15M

3.96%

+3.31M

+397.77%

Jun 30, 2025

Barry (Richard J)

3.21M

3.07%

+32.60K

+1.02%

May 16, 2025

Wellington Management Company, LLP

2.53M

2.42%

-116.16K

-4.39%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.88M

1.79%

+55.08K

+3.02%

Jun 30, 2025

Erste Asset Management GmbH

1.62M

1.55%

+560.35K

+52.81%

Jun 30, 2025

Qube Research & Technologies Ltd

1.60M

1.53%

+1.57M

+4909.63%

Jun 30, 2025

持股ETF



更新时间: 10月6日周一

机构名称

占比

First Trust NYSE Arca Biotechnology Index Fund

3.25%

iShares Neuroscience and Healthcare ETF

1.62%

Invesco S&P SmallCap Health Care ETF

1.21%

Global X Genomics & Biotechnology ETF

1.11%

Virtus LifeSci Biotech Products ETF

0.81%

Invesco S&P SmallCap 600 Pure Growth ETF

0.66%

SPDR S&P Biotech ETF

0.65%

WisdomTree BioRevolution Fund

0.43%

Direxion Daily S&P Biotech Bull 3X Shares

0.4%

VanEck Biotech ETF

0.35%

First Trust NYSE Arca Biotechnology Index Fund

占比3.25%

iShares Neuroscience and Healthcare ETF

占比1.62%

Invesco S&P SmallCap Health Care ETF

占比1.21%

Global X Genomics & Biotechnology ETF

占比1.11%

Virtus LifeSci Biotech Products ETF

占比0.81%

Invesco S&P SmallCap 600 Pure Growth ETF

占比0.66%

SPDR S&P Biotech ETF

占比0.65%

WisdomTree BioRevolution Fund

占比0.43%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.4%

VanEck Biotech ETF

占比0.35%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据